African populations are currently underrepresented in global psychiatric genetics research. Here, we highlight the importance of conducting psychiatric genetics research in Africa, key issues which have hindered such research, and ongoing initiatives and strategies to overcome these issues.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11511995 | PMC |
| http://dx.doi.org/10.1038/s43856-024-00639-z | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The Fetal Environment and the Development of Hypertension-The Epigenetic Modification by Glucocorticoids.
Int J Mol Sci
January 2025
Department of Clinical Laboratory, School of Medicine, International University of Health and Welfare, Otawara 324-8501, Japan.
Intrauterine growth restriction (IUGR) is a risk factor for postnatal cardiovascular, metabolic, and psychiatric disorders. In most IUGR models, placental dysfunction that causes reduced 11β-hydroxysteroid dehydrogenase 2 (11βHSD2) activity, which degrades glucocorticoids (GCs) in the placenta, resulting in fetal GC overexposure. This overexposure to GCs continues to affect not only intrauterine fetal development itself, but also the metabolic status and neural activity in adulthood through epigenetic changes such as microRNA change, histone modification, and DNA methylation.
View Article and Find Full Text PDFComparative Analysis of Serum BAFF and IL-17 Levels Pre- and Post-Antipsychotic Treatment for Acute Schizophrenia.
Int J Mol Sci
January 2025
Research Laboratory LR12ES04, Faculty of Medicine of Sousse, University of Sousse, Sousse 4002, Tunisia.
The interplay between the cytokine network and antipsychotic treatment in schizophrenia remains poorly understood. This study aimed to investigate the impact of psychotropic medications on serum levels of IFN-γ, IL-4, TGF-β1, IL-17, and BAFF, and to explore their relationship with psychopathological features. We recruited 63 patients diagnosed with schizophrenia in the acute phase, all of whom were either drug-naïve or had been drug-free for at least three months.
View Article and Find Full Text PDFOptimization of antidepressant treatment by pharmacogenomics: a case report.
BMC Psychiatry
January 2025
Institute of Mental Health, Peking University Sixth Hospital, Beijing, 100191, China.
Background: Few new psychiatric drugs have entered the market in recent decades; in contrast, the number of drugs carrying pharmacogenomic labels continues to increase. For the foreseeable future, the advancement of psychiatry and drug therapy may hinge on personalized treatment. Currently, antipsychotic or antidepressant choices rely heavily on the clinical experience of psychiatrists and potentially lengthy iterative trials.
View Article and Find Full Text PDFPrenatal maternal stress in rats alters the epigenetic and transcriptomic landscape of the maternal-fetal interface across four generations.
Commun Biol
January 2025
Department of Neuroscience, Canadian Centre for Behavioural Neuroscience, University of Lethbridge, University Drive Lethbridge, Lethbridge, AB, Canada.
Prenatal maternal stress (PNMS) determines lifetime mental and physical health. Here, we show in rats that PNMS has consequences for placental function and fetal brain development across four generations (F0-F3). Using a systems biology approach, comprehensive DNA methylation (DNAm), miRNA, and mRNA profiling revealed a moderate impact of PNMS in the F1 generation, but drastic changes in F2 and F3 generations, suggesting compounding effects of PNMS with each successive generation.
View Article and Find Full Text PDFPlasma microRNA Levels After Electroconvulsive Therapy in Treatment-Resistant Depressed Patients.
J ECT
January 2025
Division of Biology and Genetics, Department of Molecular and Translational Medicine, University of Brescia, Brescia.
Objectives: Electroconvulsive therapy (ECT) is one of the most effective treatments for treatment-resistant depression (TRD), even though the molecular mechanisms underlying its efficacy remain largely unclear. This study aimed, for the first time, to analyze plasma levels of miRNAs, key regulators of gene expression, in TRD patients undergoing ECT to investigate potential changes during treatment and their associations with symptom improvement.
Methods: The study involved 27 TRD patients who underwent ECT.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!